|
Variable
|
Without variceal bleeding
|
With variceal bleeding
|
Univariate analysis
|
Multivariate analysis
|
|---|
|
(n = 196)
|
(n = 10)
|
HR
|
95% CI
|
P-value
|
HR
|
95% CI
|
P-value
|
|---|
|
Age (years)
|
55.6 ± 9.5
|
52.9 ± 7.9
|
0.979
|
0.916–1.045
|
0.523
| | | |
|
Male
|
173 (88.3)
|
8 (80.0)
|
2.023
|
0.428–9.566
|
0.374
| | | |
|
Hypertension
|
42 (21.4)
|
2 (20.0)
|
0.997
|
0.210–4.723
|
0.997
| | | |
|
HBV infection
|
173 (88.3)
|
10 (100.0)
| | | | | | |
|
Child-Pugh class
|
|
A (reference)
|
174 (88.8)
|
10 (100.0)
| | | | | | |
|
B
|
22 (11.2)
|
0 (0.0)
| | | | | | |
|
NSBBs
|
36 (18.4)
|
2 (20.0)
|
1.283
|
0.270–6.090
|
0.754
| | | |
|
PT (INR)
|
1.1 ± 0.1
|
1.2 ± 0.1
|
1.956
|
1.191–3.210
|
0.008
| | | |
|
Creatinine (mg/dl)
|
0.9 ± 0.1
|
0.9 ± 0.2
|
0.774
|
0.112–5.355
|
0.795
| | | |
|
Platelet count (×103/uL)
|
140.1 ± 64.2
|
127.2 ± 51.4
|
0.996
|
0.985–1.007
|
0.528
| | | |
|
AST (IU/L)
|
57.5 ± 48.8
|
48.3 ± 26.4
|
0.995
|
0.976–1.013
|
0.576
| | | |
|
ALT (IU/L)
|
43.9 ± 40.8
|
40.2 ± 29.1
|
0.997
|
0.975–1.018
|
0.758
| | | |
|
Ascites
|
18 (9.2)
|
0 (0.0)
| | | | | | |
|
Number of tumors
|
|
Single (reference)
|
109 (55.6)
|
6 (60.0)
|
1.0
|
–
|
–
| | | |
|
Multiple
|
87 (44.4)
|
4 (40.0)
|
1.151
|
0.316–4.194
|
0.831
| | | |
|
Tumor size (cm)
|
7.1 ± 3.5
|
8.4 ± 4.9
|
1.237
|
0.258–5.929
|
0.790
| | | |
|
Serum AFP (ng/ml)
|
13,429.2 ± 45,167.2
|
8230.8 ± 18,268.5
|
1.154
|
0.976–1.364
|
0.093
| | | |
|
Extrahepatic metastasis
|
41 (20.9)
|
2 (20.0)
|
0.998
|
0.976–1.021
|
0.875
| | | |
|
Degree of PVTT
|
|
Vp2 (reference)
|
74 (37.7)
|
2 (20.0)
|
1.0
|
–
|
–
| | | |
|
Vp3
|
45 (23.0)
|
3 (30.0)
|
2.464
|
0.406–14.924
|
0.327
| | | |
|
Vp4
|
77 (39.3)
|
5 (50.0)
|
2.965
|
0.567–15.497
|
0.198
| | | |
|
Primary anti-HCC treatment
|
|
TACE
|
133 (67.9)
|
7 (70.0)
|
1.174
|
0.302–4.574
|
0.817
| | | |
|
Radiotherapy
|
52 (26.5)
|
2 (20.0)
|
0.753
|
0.160–3.554
|
0.720
| | | |
|
Sorafenib
|
9 (4.6)
|
3 (30.0)
|
11.615
|
2.809–48.030
|
0.001
|
5.676
|
1.273–25.300
|
0.023
|
|
High-risk varices
|
49 (25.0)
|
9 (90.0)
|
31.323
|
3.928–249.782
|
0.001
|
26.432
|
3.230–216.289
|
0.002
|
- Values are expressed as the mean ± standard deviation, or frequency (percentage)
- PVTT portal vein tumor thrombosis, HR hazards ratio, CI confidence interval, HBV hepatitis B virus, NSBB nonselective beta-blocker, PT prothrombin time, INR international normalized ratio, AST aspartate aminotransferase, ALT alanine aminotransferase, AFP alpha-fetoprotein, HCC hepatocellular carcinoma, and TACE transarterial chemoembolization
